November 05, 2019

A Biosimilars Update

If you're wondering about the status of biosimilars since the first biosimilar Inflectra was approved by the FDA in 2016, then this webinar is for you!  Hear Dr. Paul Yamauchi, dermatologist at Dermatology Institute and Skin Care Center, Clinical Science Institute in Santa Monica, Ca. and key opinion leader in the field of psoriasis, present the differences between a biologic and a biosimilar, current and upcoming biosimilars, and implications as a treatment option.  


Contact Bev Bromfield, Outreach Manager, at or 800-723-9166, ext. 362.

The views and opinions expressed in the webinars are those of the speakers. The speakers' views and opinions are not endorsed by the National Psoriasis Foundation or its sponsors.

Related Items

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2023 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.